insights_auto
Why is LSTA up ၂.၄၉%?
Dive Deeperchevron_right
LSTA:NASDAQ
Lisata Therapeutics, Inc.
၁.၀၃ US$
arrow_upward
+၂.၄၉%(+၀.၀၂၅) 1D
နို ၆, GMT-၅ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
၁.၀၂ US$
High
၁.၀၆ US$
Low
၀.၉၉ US$
Mkt. cap
၁.၁၁ ကုဋေ
Avg. vol.
၉.၀၂ သောင်း
Volume
၁.၄၉ သောင်း
52-wk high
၅.၀၆ US$
52-wk low
၀.၉၆ US$
EPS
-၁.၆၄ US$
Beta
၁.၀၄
Shares outstanding
၁.၀၈ ကုဋေ
No. of employees
၂၁
Open
၁.၀၂ US$
High
၁.၀၆ US$
Low
၀.၉၉ US$
Mkt. cap
၁.၁၁ ကုဋေ
Avg. vol.
၉.၀၂ သောင်း
Volume
၁.၄၉ သောင်း
52-wk high
၅.၀၆ US$
52-wk low
၀.၉၆ US$
EPS
-၁.၆၄ US$
Beta
၁.၀၄
Shares outstanding
၁.၀၈ ကုဋေ
No. of employees
၂၁
News stories
From web sources and news partners
Kiplinger
·
ပြီးခဲ့သည့် ၁၀ မိနစ်
Nasdaq Adds 264 Points as Tech Stocks Rebound, But Ends the Week Lower: Stock Market Today
TradingView
·
ပြီးခဲ့သည့် ၂ နာရီ
QQQ Vs. TQQQ: 3X Nasdaq ETFs Compounding Trap Is Costing Investors Big
Benzinga
·
ပြီးခဲ့သည့် ၁၄ မိနစ်
12 Industrials Stocks Moving In Friday's After-Market Session
Seeking Alpha
·
ပြီးခဲ့သည့် ၉ မိနစ်
U.S. indexes will hit new highs within three months, says SA analyst
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees၂၁
Founded၁၉၈၀
HeadquartersBasking Ridge, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitelisata.com